The relationship between sleep disorders and cognitive health has become an important focus of brain health research. Sleep disorders are associated with a significantly higher risk of Alzheimer's disease and all-cause dementia, and the biological mechanisms involving the brain's own waste-clearance system are increasingly better understood.
GLP-1/GIP therapies are reshaping OSA care, but their arrival has exposed a critical guideline gap. Current guidelines lack operational direction on reassessment, multimodal sequencing and therapy discontinuation, risking unverified disease resolution assumptions and unsafe therapy abandonment.
